FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs for Extensive Stage SCLC By Ogkologos - October 16, 2025 187 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Intratumoural and Intracavitary Administration of Ipilimumab Plus Nivolumab Is Feasible and... December 12, 2020 TRACERx: Using blood tests to track lung cancer May 1, 2023 Metastatic Breast Cancer: New ESMO Guideline With Evidence-Based Recommendations [ESMO Press... October 19, 2021 Building a Support Community During Cancer: “Your Stories” Podcast December 14, 2021 Load more HOT NEWS FDA Grants Traditional Approval to Selpercatinib for RET Fusion-positive Thyroid Cancer Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced... FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or... Grief Anniversaries
